Pretty underwhelming market reaction today. I went back
Pretty underwhelming market reaction today. I went back and looked at when we got the SeD LOI announcement a year ago to the day, Feb 27, 2017. The stock did nothing for several days and didn't hit its high for that time until 10 day later on March 10th, so maybe we will see a similar delayed response here too.
Today's news is a HUGE turning point and not sure people realize it yet. It is the removal of the death spiral toxic financing- they have settled. There is a lot more that has to happen, but this HAD to be the first step and is the MOST important step for the company to turn around. The Company has not been able to do any kind of JV partnership or raise any money with the toxics hanging on them these past 2-1/2 years- they have been dead in the water. This changes everything. I see the following upcoming catalysts in the near future:
Completion of the Tender Exchange - by March 17th
Completion of the requisition of the Diagnostics assets from Avant- they are getting back all of the diagnostics that Gerald basically gave away 2 years ago- again a HUGE step forward. This will probably be completed very soon- pretty simple deal because the only principles to the deal are Gerald and Scott Vandermeer. They are giving Avant a million shares, but they get 30 million shares of Avant in return, so basically they are getting the assets for free- it is like a "do-over" for Amarantus.
Settlement of the Greentree Suit- The Plaintiff keeps extending the Case management date, which they don't have to do, so I know they are in discussions with them and I expect they will work out a payment plan.
7
Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Quantum Space Bags a Chunk of NASA's Lunar Ambitions Alright, folks, buckle up because we're about to dive into the cosmos. Quantum Space just nabbed a sweet deal—a $185 million whopper of a contract from NASA's Moon Base Transportation program. This isn't chump change; it's a 25% slice for Quantum from the lot Arrow Science and Technology is heading. We're talking...
Continue Reading
NASA's Vision and Impulse's New Role Ever think you'd see a company like Impulse Space set to play a starring role in humanity's return to the lunar surface? Well, strap in because this isn't just a pipe dream anymore. NASA's bold plan to establish a Moon Base has taken a tangible step forward with Impulse winning two hefty task orders. This ain't just peanuts—this duo...
Continue Reading
Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...
Continue Reading
Securities Fraud Allegations Hit AST SpaceMobile Days like this remind me why we keep our eyes peeled in the stock game—AST SpaceMobile (NASDAQ: ASTS) is tangled in a web of legal drama, and it's something you can't brush off with a shrug. Class action lawsuits for securities fraud? That's like finding out the foundation's shaky beneath a skyscraper. If you've got skin...
Continue Reading
Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...
Continue Reading
Exploring New Horizons in Display Technology There's something brewing in Wuhan: a conference that’s shaping up like a tech enthusiast’s dream. This year, it's all about the symbiosis of cutting-edge tech and dazzling visuals as TCL CSOT gears up to unveil advancements at the Global Display Tech-Ecosystem Conference (DTC) 2026. If you're wondering whether this event...
Continue Reading
Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...
Continue Reading
Data Breach Fallout: Amplifon Under Fire When a big player like Amplifon gets hit with a data breach, it's like a wake-up call across the board. This one’s no small spill—over 1.3 million folks left wondering whether their personal information is fluttering around cyberspace for all who dare to peek. If you’ve missed the memo, Edelson Lechtzin LLP, the savvy cats in...
Continue Reading
China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...
Continue Reading
The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....
Continue Reading
Top 5 Most Recently Viewed Articles
Avacta Therapeutics Presents FAP-Dox Data at International Congress Avacta Therapeutics, a pioneering life sciences company, is set to present an exciting update regarding their innovative drug FAP-Dox (AVA6000) at an esteemed international oncology congress. This event will spotlight groundbreaking research and clinical advancements in targeted cancer treatments that can...
Continue Reading
Strategic Collaboration Between Qvinci and Harmonyze In a remarkable development, Qvinci Software, renowned for its innovative franchise financial performance solutions, has announced a pivotal partnership with Harmonyze, an AI-driven performance coaching platform. This collaboration is designed to assist franchisors in transforming intricate financial insights into...
Continue Reading
Outlook for Capgemini Stock Citi analyst Balajee Tirupati has recently made adjustments to the price target for Capgemini SE (CAP:FP) (OTC: CAPMF), reducing it to €215 from €225. Despite this revision, Citi has maintained a positive stance, continuing to endorse a Buy rating for Capgemini's stock. Weaker Third-Quarter Update Capgemini's recent third-quarter report for...
Continue Reading
Beyond Oil's Successful Expansion into the Australian Market Following its commitment to health and sustainability, Beyond Oil Ltd. (CSE: BOIL, OTCQB: BEOLF) has successfully delivered its first shipment of 5.4 tonnes of proprietary oil treatment products to T&J Oil Pty Ltd. This marks an important leap for the company as it steps into the Australian distribution arena,...
Continue Reading
Donaldson's Commitment to Community Engagement Donaldson Company, Inc. (NYSE: DCI), a leader in innovative filtration solutions, has taken a significant step towards community engagement by announcing its partnership with the 2026 Special Olympics USA Games. This event is set to create a platform for inclusion, offering athletes with diverse abilities an opportunity to...
Continue Reading